

DOCKET NO.: IBIS-0012



APR 17 2000
TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Ecker, Sampath, Griffey and McNeil

Serial No.: 09/310,667

Group Art Unit: 1655

Filing Date: May 12, 1999

Examiner: F. Lu

For: IDENTIFICATION OF MOLECULAR INTERACTION SITES IN RNA FOR
NOVEL DRUG DISCOVERY

DATE OF DEPOSIT: 7 APRIL 2000

I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID
ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, DC 20231.

Paul K. Leggard
TYPED NAME: Paul K. Leggard
REGISTRATION NO.: 38,534

Box ☒ NON-FEE

☐ AF

Assistant Commissioner for Patents
Washington DC 20231

Sir:

AMENDMENT TRANSMITTAL LETTER

Transmitted herewith for filing in the above-identified patent application is:

- ☐ A Preliminary Amendment.
- ☒ A Response to the Restriction Requirement Dated March 14, 2000.
- ☐ An Amendment Supplemental to the Paper filed _____
- ☐ Other: _____

- ☒ Small entity status of this application under 37 C.F.R. 1.9 and 1.27 was established in a previous submission.
- ☐ A Statement Claiming Small Entity Status under 37 C.F.R. 1.9 and 1.27 is enclosed.
- ☐ This application is no longer entitled to small entity status. It is requested that this be noted in the files of the Patent and Trademark Office.
- ☐ Substitute Pages _____ of the Specification are enclosed.
- ☐ An Abstract is enclosed.
- ☐ _____ Sheets of Proposed Corrected Drawings are enclosed.
- ☐ A Certified Copy of each of the following applications: _____
_____ is enclosed.
- ☐ An Associate Power of Attorney is enclosed.
- ☐ Information Disclosure Statement.
- ☐ Attached Form 1449.
- ☐ A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.
- ☐ Appended Material as follows: _____
- ☐ Other Material as follows: _____

FEE CALCULATION

☒ No Additional Fee is Due.

				SMALL ENTITY		NOT SMALL ENTITY	
	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	RATE	FEE	RATE	FEE
TOTAL CLAIMS	34	34 (20 MINIMUM)	0	\$9 EACH	\$0	\$18 EACH	\$
INDEP. CLAIMS	6	6 (3 MINIMUM)	0	\$39 EACH	\$0	\$78 EACH	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT				\$130	\$0	\$260	\$
<input type="checkbox"/> ONE MONTH EXTENSION OF TIME				\$55	\$0	\$110	\$
<input type="checkbox"/> TWO MONTH EXTENSION OF TIME				\$190	\$0	\$380	\$
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME				\$435	\$0	\$870	\$
<input type="checkbox"/> FOUR MONTH EXTENSION OF TIME				\$680	\$0	\$1360	\$
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME				\$925	\$0	\$1850	\$
<input type="checkbox"/> LESS ANY EXTENSION FEE ALREADY PAID				minus	(\$0)	minus	(\$)
<input type="checkbox"/> TERMINAL DISCLAIMER				\$55	\$0	\$110	\$
<input type="checkbox"/> OTHER FEE OR SURCHARGE AS FOLLOWS:					0		
TOTAL FEE DUE					\$0		\$

- ☐ A Check is Enclosed in the Foregoing Amount Due.
- ☐ Petition is hereby made under 37 C.F.R. 1.136(a) to extend the time for response to the Office Action of @@ to and through @@ comprising an extension of the shortened statutory period of @@ month(s).
- ☒ The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit

APR 17 2000

DOCKET NO.: IBIS-0012

- 4 -


TECH CENTER 1600/2900 PATENT

account 23-3050. This sheet is provided in duplicate.

- ☒ The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.
- ☐ The Foregoing Amount Due for Filing this Paper.
- ☒ Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.
- ☒ Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: 7 APRIL 2000


Paul K. Legaard
Registration No. 38,534

Woodcock Washburn Kurtz
Mackiewicz & Norris LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 1997 WWKMN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ecker, Sampath, Griffey and McNeil

Serial No.: 09/310, 667

Group Art Unit: 1655

Filed: May 12, 1999


Examiner: F. Lu

For: **IDENTIFICATION OF MOLECULAR INTERACTION SITES IN RNA
FOR NOVEL DRUG DISCOVERY**



I, Paul K. Legaard, Registration No. 38,534 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On April 7, 2000


Paul K. Legaard Reg. No. 38,534

Assistant Commissioner for
Patents
Washington, D.C. 20231

Dear Sir:

RESPONSE TO THE RESTRICTION REQUIREMENT


The present Response is filed in response to the Restriction Requirement mailed March 14, 2000 in connection with the above-identified patent application.

The Examiner has restricted claims 1-34 into five groups. Group I contains claims 1-11 drawn to methods of identifying molecular interaction sites in a target nucleic acid. Group II contains claims 12-20 drawn to methods of identifying molecular interaction sites in a target nucleic acid using nucleic acid sequence information from genetic databases. Group III contains claims 22-25 drawn to databases. Group IV contains claims 26-29 drawn to oligonucleotides comprising a molecular interaction site. Group V contains claims 30-34 drawn to pharmaceutical compositions.

As a preliminary matter, Applicants direct the Examiner's attention to the parent application U.S. Serial No. 09/076,440 which, as filed, contained claims identical to all claims originally filed in the present application. Applicants point out the inconsistency between the Restriction Requirement imposed in the parent application, in which the claims were restricted into four groups, versus the present application, in which the claims have been restricted into five groups. In any event, Applicants elect herein group IV containing claims 26-29 directed to oligonucleotides comprising a molecular interaction site.

Applicants submit that the present response is complete and complies with the requirements of 35 U.S.C. § 121.

Respectfully submitted,



Paul K. Legaard

Registration No. 38,534

Date: **April 7, 2000**

WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439